199 related articles for article (PubMed ID: 8361758)
1. Several mutant p53 proteins detected in cancer-prone families with Li-Fraumeni syndrome exhibit transdominant effects on the biochemical properties of the wild-type p53.
Srivastava S; Wang S; Tong YA; Pirollo K; Chang EH
Oncogene; 1993 Sep; 8(9):2449-56. PubMed ID: 8361758
[TBL] [Abstract][Full Text] [Related]
2. Dominant negative effect of a germ-line mutant p53: a step fostering tumorigenesis.
Srivastava S; Wang S; Tong YA; Hao ZM; Chang EH
Cancer Res; 1993 Oct; 53(19):4452-5. PubMed ID: 8402611
[TBL] [Abstract][Full Text] [Related]
3. Detection of both mutant and wild-type p53 protein in normal skin fibroblasts and demonstration of a shared 'second hit' on p53 in diverse tumors from a cancer-prone family with Li-Fraumeni syndrome.
Srivastava S; Tong YA; Devadas K; Zou ZQ; Sykes VW; Chen Y; Blattner WA; Pirollo K; Chang EH
Oncogene; 1992 May; 7(5):987-91. PubMed ID: 1373881
[TBL] [Abstract][Full Text] [Related]
4. A germline 2.35 kb deletion of p53 genomic DNA creating a specific loss of the oligomerization domain inherited in a Li-Fraumeni syndrome family.
Plummer SJ; Santibáñez-Koref M; Kurosaki T; Liao S; Noble B; Fain PR; Anton-Culver H; Casey G
Oncogene; 1994 Nov; 9(11):3273-80. PubMed ID: 7936651
[TBL] [Abstract][Full Text] [Related]
5. A functionally inactive p53 Li-Fraumeni syndrome mutant.
Hao M; Finlay CA; Lozano G
Oncogene; 1993 Feb; 8(2):299-306. PubMed ID: 8426739
[TBL] [Abstract][Full Text] [Related]
6. Tissue-specific expression of SV40 in tumors associated with the Li-Fraumeni syndrome.
Malkin D; Chilton-MacNeill S; Meister LA; Sexsmith E; Diller L; Garcea RL
Oncogene; 2001 Jul; 20(33):4441-9. PubMed ID: 11494139
[TBL] [Abstract][Full Text] [Related]
7. In vitro analysis of the dominant negative effect of p53 mutants.
Chène P
J Mol Biol; 1998 Aug; 281(2):205-9. PubMed ID: 9698540
[TBL] [Abstract][Full Text] [Related]
8. Germ-line exclusion of a single p53 allele by premature termination of translation in a Li-Fraumeni syndrome family.
Stolzenberg MC; Brugières L; Gardes M; Dessarps-Freichey F; Chompret A; Bressac B; Lenoir G; Bonaïti-Pellié C; Lemerle J; Feunteun J
Oncogene; 1994 Oct; 9(10):2799-804. PubMed ID: 8084585
[TBL] [Abstract][Full Text] [Related]
9. Identification and characterization of a novel germ line p53 mutation in familial gastric cancer in the Japanese population.
Yamada H; Shinmura K; Okudela K; Goto M; Suzuki M; Kuriki K; Tsuneyoshi T; Sugimura H
Carcinogenesis; 2007 Sep; 28(9):2013-8. PubMed ID: 17690113
[TBL] [Abstract][Full Text] [Related]
10. Characterization of the oligomerization defects of two p53 mutants found in families with Li-Fraumeni and Li-Fraumeni-like syndrome.
Davison TS; Yin P; Nie E; Kay C; Arrowsmith CH
Oncogene; 1998 Aug; 17(5):651-6. PubMed ID: 9704931
[TBL] [Abstract][Full Text] [Related]
11. Cancer phenotype correlates with constitutional TP53 genotype in families with the Li-Fraumeni syndrome.
Birch JM; Blair V; Kelsey AM; Evans DG; Harris M; Tricker KJ; Varley JM
Oncogene; 1998 Sep; 17(9):1061-8. PubMed ID: 9764816
[TBL] [Abstract][Full Text] [Related]
12. Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype.
Olivier M; Goldgar DE; Sodha N; Ohgaki H; Kleihues P; Hainaut P; Eeles RA
Cancer Res; 2003 Oct; 63(20):6643-50. PubMed ID: 14583457
[TBL] [Abstract][Full Text] [Related]
13. A germ line mutation in exon 5 of the p53 gene in an extended cancer family.
Law JC; Strong LC; Chidambaram A; Ferrell RE
Cancer Res; 1991 Dec; 51(23 Pt 1):6385-7. PubMed ID: 1933902
[TBL] [Abstract][Full Text] [Related]
14. [Germline mutations of the p53 gene].
Frebourg T
Pathol Biol (Paris); 1997 Dec; 45(10):845-51. PubMed ID: 9769948
[TBL] [Abstract][Full Text] [Related]
15. Germ-line splicing mutation of the p53 gene in a cancer-prone family.
Warneford SG; Witton LJ; Townsend ML; Rowe PB; Reddel RR; Dalla-Pozza L; Symonds G
Cell Growth Differ; 1992 Nov; 3(11):839-46. PubMed ID: 1467311
[TBL] [Abstract][Full Text] [Related]
16. [Li-Fraumeni syndrome and germ-line mutations of the p53 gene].
Leblanc T; Soussi T
Arch Pediatr; 1994 Jan; 1(1):61-70. PubMed ID: 8087224
[TBL] [Abstract][Full Text] [Related]
17. Cancer risks from germ line tumor suppressor gene mutations.
Frebourg T; Malkin D; Friend S
Princess Takamatsu Symp; 1991; 22():61-70. PubMed ID: 1844252
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the molecular mechanisms involved in the gain of function of a Li-Fraumeni TP53 mutation.
Capponcelli S; Pedrini E; Cerone MA; Corti V; Fontanesi S; Alessio M; Bachi A; Soddu S; Ribatti D; Picci P; Helman LJ; Cantelli-Forti G; Sangiorgi L
Hum Mutat; 2005 Aug; 26(2):94-103. PubMed ID: 15977174
[TBL] [Abstract][Full Text] [Related]
19. Joint effects of germ-line p53 mutation and sex on cancer risk in Li-Fraumeni syndrome.
Wu CC; Shete S; Amos CI; Strong LC
Cancer Res; 2006 Aug; 66(16):8287-92. PubMed ID: 16912210
[TBL] [Abstract][Full Text] [Related]
20. Germ-line mutations of the p53 tumor suppressor gene in patients with high risk for cancer inactivate the p53 protein.
Frebourg T; Kassel J; Lam KT; Gryka MA; Barbier N; Andersen TI; Børresen AL; Friend SH
Proc Natl Acad Sci U S A; 1992 Jul; 89(14):6413-7. PubMed ID: 1631137
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]